NEW YORK – VieCure on Tuesday announced the closing of a $25 million Series A funding round led by Northpond Ventures.
The Denver-based startup will use the funding to deploy its next generation clinical decision support solution and to expand the sales and business development organization of the company. In concordance with the funding, Andrea Jackson, director for Northpond Ventures, will join the new VieCure board of directors.
VieCure's platform uses artificial intelligence to combine patient data with clinical trial data to create treatment plans and manage care through a cancer patient's diagnosis, treatment, and follow-up care. The platform is used by surgical oncologists, medical oncologists, radiation oncologists, hematologists, and clinical trial investigators.
Its platform also includes a clinical content library to help oncologists stay on top of the latest medical research in precision oncology, a patient engagement app, electronic medical records, patient and practice data and analytics tool, and a telemedicine capability.
"The VieCure platform is an ideal operating solution for oncologists, nurses, pharmacists, and clinical trial professionals, given it is designed for the precision oncology era and supports clinical decision making at point-of-care," Jackson said in a statement. "The precision oncology paradigm shift is underway and the amount of data that clinicians are being expected to digest, consider, and action is often beyond the human condition. The VieCure platform ingests these data discretely, inferences these data against the latest clinical evidence and trial protocols, and generates optimal treatment plan considerations for action while the patient is in the exam room."
The company has partnered with health systems and cancer centers, like The Center for Cancer and Blood Disorders in Texas and Alabama Cancer Care. The partnership with Alabama Cancer Care will use VieCure's platform to accelerate the adoption and delivery of precision oncology across the health system.
In addition, several companies including Sema4, Ion Solutions, TD2, and Thinking Systems are using the VieCure platform to improve workflow and increase adoption of precision oncology among their oncology partners, VieCure said.